{
    "1646211730073174047": {
        "attachments": {
            "media_keys": [
                "13_1646211583255756808"
            ]
        },
        "author_id": "62465691",
        "created_at": "2023-04-12T18:00:36.000Z",
        "edit_history_tweet_ids": [
            "1646211730073174047"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 147,
                    "normalized_text": "cancer",
                    "probability": 0.5411,
                    "start": 142,
                    "type": "Other"
                },
                {
                    "end": 236,
                    "normalized_text": "AACR23",
                    "probability": 0.6577,
                    "start": 231,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 237,
                    "start": 230,
                    "tag": "AACR23"
                }
            ],
            "urls": [
                {
                    "display_url": "pic.twitter.com/yAHNvFh2b3",
                    "end": 261,
                    "expanded_url": "https://twitter.com/AstraZeneca/status/1646211730073174047/video/1",
                    "media_key": "13_1646211583255756808",
                    "start": 238,
                    "url": "https://t.co/yAHNvFh2b3"
                }
            ]
        },
        "id": "1646211730073174047",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 2,
            "impression_count": 10188,
            "like_count": 50,
            "quote_count": 4,
            "reply_count": 20,
            "retweet_count": 6
        },
        "text": "We\u2019re advancing our oncology portfolio with innovations in cell therapy, immuno-oncology, antibody-drug conjugates and epigenetics, to attack cancer from multiple angles and bring potentially transformative medicines to patients. #AACR23 https://t.co/yAHNvFh2b3"
    }
}